Aspirin Discontinuation in High-Risk Pregnant Women of Preeclampsia

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

Low-dose aspirin (LDA) is considered to be the most effective agent to prevent preeclampsia (PE). At present, there is little exploration about the timing of aspirin discontinuation. Most international guidelines default until 36 weeks of gestation or delivery. China Guideline (2020) recommended that aspirin should be preventively used until 26-28 weeks of gestation, but there was little direct evidence. According to the two-stage theory, placental dysplasia before 28 weeks of gestation is the key to developing PE, the significance of aspirin use after 28 weeks of gestation is debatable. If aspirin discontinuation at 28 weeks of gestation is proven to be feasible for preventing preterm PE, it will not only reduce the risk of Perinatal Haemorrhage but also save medical expenses.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: FANG HE
• Treatments: Aspirin

Criteria

Inclusion Criteria:

1. At <16 weeks of gestation, normal NT scan

2. At least 1 high risk factor or at least 2 moderate risk factors

3. Intend to receive prenatal examination and deliver in this institution

4. Signed a written informed consent for participation in the study

Exclusion Criteria:

1. Aspirin initiated after 16 week

2. Intolerant or allergic to aspirin

3. Aspirin adherence was <80%

4. Miscarriage or termination of pregnancy before randomization

5. drop out (do not return to the hospital for delivery).

6. Lost to follow-up